Cardio-renal complications in type 2 diabetes at the first add-on to metformin: an international retrospective study

2021 ◽  
Author(s):  
Cristian Guja
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Renal Complications

RISK-1: One-year Retrospective Study to Assess Cardiovascular Risk at the Onset of Type 2 Diabetes Mellitus in Slovenia

Metabolism ◽  
2021 ◽  
Vol 116 ◽  
pp. 154481
Author(s):  
Iris Marolt ◽  
Jana Komel ◽  
Elena Kuzmina ◽  
Anja Babič ◽  
Renata Kopriva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Risk ◽  
Retrospective Study ◽  
One Year

scholarly journals Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

Diabetologia ◽  
2021 ◽  
Author(s):  
Johanne Tremblay ◽  
Mounsif Haloui ◽  
Redha Attaoua ◽  
Ramzan Tahir ◽  
Camil Hishmih ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
High Risk ◽  
Glucose Control ◽  
Risk Group ◽  
Cardiovascular Death ◽  
Polygenic Risk ◽  
Renal Complications ◽  
Intensive Blood Pressure

Abstract Aims/hypothesis Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction could lead to timely intervention and better outcomes. Genetic information can be used to enable early detection of risk. Methods We developed a multi-polygenic risk score (multiPRS) that combines ten weighted PRSs (10 wPRS) composed of 598 SNPs associated with main risk factors and outcomes of type 2 diabetes, derived from summary statistics data of genome-wide association studies. The 10 wPRS, first principal component of ethnicity, sex, age at onset and diabetes duration were included into one logistic regression model to predict micro- and macrovascular outcomes in 4098 participants in the ADVANCE study and 17,604 individuals with type 2 diabetes in the UK Biobank study. Results The model showed a similar predictive performance for cardiovascular and renal complications in different cohorts. It identified the top 30% of ADVANCE participants with a mean of 3.1-fold increased risk of major micro- and macrovascular events (p = 6.3 × 10−21 and p = 9.6 × 10−31, respectively) and a 4.4-fold (p = 6.8 × 10−33) higher risk of cardiovascular death. While in ADVANCE overall, combined intensive blood pressure and glucose control decreased cardiovascular death by 24%, the model identified a high-risk group in whom it decreased the mortality rate by 47%, and a low-risk group in whom it had no discernible effect. High-risk individuals had the greatest absolute risk reduction with a number needed to treat of 12 to prevent one cardiovascular death over 5 years. Conclusions/interpretation This novel multiPRS model stratified individuals with type 2 diabetes according to risk of complications and helped to target earlier those who would receive greater benefit from intensive therapy. Graphical abstract

scholarly journals Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study

Life Sciences ◽  
2021 ◽  
pp. 119371
Author(s):  
Xueqi Cheng ◽  
Siyi Xin ◽  
Yaqi Chen ◽  
Leyu Li ◽  
Wanjun Chen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study

scholarly journals Serum cystatin C is associated with subclinical atherosclerosis in patients with type 2 diabetes: A retrospective study

2017 ◽  
Vol 15 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Yu Kyung Chung ◽  
Young Ju Lee ◽  
Kye Whon Kim ◽  
Ryu Kyoung Cho ◽  
Seung Min Chung ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Retrospective Study ◽  
Cystatin C ◽  
Subclinical Atherosclerosis ◽  
Serum Cystatin C ◽  
Serum Cystatin

scholarly journals Patients characteristics associated with better glycemic response to teneligliptin and metformin therapy in type 2 diabetes: a retrospective study

2018 ◽  
Vol 5 (2) ◽  
pp. 424
Author(s):  
Pradeep V. Gadge ◽  
Roshani P. Gadge ◽  
Nikita D. Paralkar
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Retrospective Study ◽  
Blood Sugar ◽  
Therapeutic Effectiveness ◽  
Glycemic Response ◽  
Newly Diagnosed ◽  
Long Duration

Background: Teneligliptin was recently approved for type 2 diabetes (T2D) management in India and is used as monotherapy or in combination with different antidiabetic drugs. The aim of this study was to identify patients’ characteristics associated with better glycemic response to teneligliptin and metformin.Methods: A retrospective analysis of data was performed in patients of T2D with HbA1c above 7% who were treated with teneligliptin 20 mg/d as add on to metformin (500-100 mg/d) and whose follow-up data at 12-weeks was available. Fasting blood sugar (FBS) and post-prandial blood sugar (PPBS) changes were analysed.  Results: Among 66 patients included in analysis, mean age was 61.0±9.8 years and 53% were females. Median duration of diabetes was 2 years. At 12-weeks, a significant reduction PPBS was observed (mean change: -14.3 mg/dL, p=0.009) but not in FBS (mean change: -2.4 mg/dL, p=0.353). Among different patients’ characteristics, age ≤60 years (p=0.006), duration of ≤1 year (p=0.023), body-mass index ≥25 kg/m2 (p=0.009), presence of dyslipidemia (p=0.05) and absence of complications (p=0.012) were associated with significant reduction in PPBS but not in FBS.Conclusions: A younger, newly-diagnosed, obese T2D patients with dyslipidemia without any complications of diabetes can derive better therapeutic effectiveness from teneligliptin added to metformin. These findings need to be confirmed in large, prospective, long duration study.  

Sign in / Sign up

Export Citation Format

Share Document